BL-8040 is the main therapeutic candidate of BioLineRx. It is a short peptide for the treatment of stem cell mobilization, acute myeloid leukemia, and solid tumors. It has shown strong stem-cell ...
Bioline RX Ltd (NASDAQ:BLRX) is officially turning its Phase 3 GENESES clinical trial's wheels, with the Israeli drug maker revealing today the launch of evaluating its stem-cell mobilization asset BL ...
During an investor and analyst meeting hosted in New York, BioLineRx Ltd. will disclose its multi-year development plan for BL-8040, a unique platform for the treatment of hematological cancers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results